News

AddToAny

Google+ Facebook Twitter Twitter

Under the microscope: The G protein-coupled estrogen receptor

Tell me about this receptor
The G protein-coupled estrogen receptor (let’s call it the GPER) is a seven-transmembrane-domain receptor that mediates non-genomic estrogen-related signalling.

How does it work?
After ligand activation, GPER triggers multiple downstream pathways that exert diverse biological effects on the regulation of cell growth, migration and programmed cell death in a variety of tissues. 

Does that means it has some kind of relationship with cancer progression?
Bingo. As such, a better understanding of the role GPER plays in cancer biology may lead to the identification of novel therapeutic targets.

So this has been in the news then?
Yes, new US research shows that activating the GPER can not only stop pancreatic cancer from growing, but may also make tumours more visible to the immune system and thus more susceptible to modern immunotherapy.

How does the use of GPER activators differ from other anti-cancer agents?
Nearly all current cancer drugs act to block the activity of cellular proteins that are needed by not only the cancer cells, but also by normal cells. As a result, most cancer drugs are associated with major toxicity.

How does this differ?
Using the estrogenic analogue to activate GPER mirrors something that naturally occurs in the body, as GPER is already present and normally activated by estrogen, especially in women during pregnancy.

What are the implications of its natural occurrence?
As it is something the human body is already accustomed to, evidence from preclinical animal studies suggested that side effects to this approach would likely be minimal, if this procedure moves into clinical practice.

Related Articles

Diagnose crohn’s with an engineered organism

Researchers have engineered a bacterium with the necessary capabilities for diagnosing a human disease.

Genomic medicine: Coming to the clinic near you?

Dr Rameen Shakur takes a look at how biomedical science and genomics are playing a part in real-world clinical cardiology.

Unintended consequences

Computational biologist Gregorio Alanis- Lobato highlights the need for greater awareness of and further research into the effects of CRISPR-Cas9 genome editing.

The evolution of quality assessment

In 2011, UK NEQAS Cellular Pathology Technique (CPT) carried out tests across four schemes – it now covers 12 schemes with two in the pipeline. We hear from Chantell Hodgson, UK NEQAS CPT Scheme Manager.

Top